Plasminogen activator inhibitor-1 inhibitors

A patent review (2006-present)

Research output: Contribution to journalArticle

Abstract

Introduction: Plasminogen activator inhibitor-1 (PAI-1), the serine protease inhibitor (serpin), binds to and inhibits the plasminogen activators-tissue-type plasminogen activator (tPA) and the urokinase-type plasminogen activator (uPA). This results in both a decrease in plasmin production and a decrease in the dissolution of fibrin clots. Elevated levels of PAI-1 are correlated with an increased risk for cardiovascular disease and have been linked to obesity and metabolic syndrome. Consequently, the pharmacological suppression of PAI-1 might prevent or treat vascular disease. Areas covered: This article provides an overview of the patenting activity on PAI-1 inhibitors. Patents filed by pharmaceutical companies or individual research groups are described, and the biological and biochemical evaluation of the inhibitors, including in vitro and in vivo studies, is discussed. An overview of patents pertaining to using these inhibitors for treating various diseases is also included. Expert opinion: Although there is still no PAI-1 inhibitor being evaluated in a clinical setting or approved for human therapy, research in this field has progressed, and promising new compounds have been designed. Most research has focused on improving the pharmacological profile of these compounds, which will hopefully allow them to proceed to clinical studies. Despite the need for further testing and research, the potential use of PAI-1 inhibitors for treating cardiovascular disease appears quite promising.

Original languageEnglish (US)
Pages (from-to)801-815
Number of pages15
JournalExpert Opinion on Therapeutic Patents
Volume23
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Plasminogen Activator Inhibitor 1
Patents
Research
Cardiovascular Diseases
Pharmacology
Serine Proteinase Inhibitors
Plasminogen Activators
Fibrinolysin
Urokinase-Type Plasminogen Activator
Expert Testimony
Tissue Plasminogen Activator
Fibrin
Vascular Diseases
Obesity
Pharmaceutical Preparations

Keywords

  • Antagonist
  • Inhibitors
  • PAI-1
  • Plasminogen
  • Serpin

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Plasminogen activator inhibitor-1 inhibitors : A patent review (2006-present). / Fortenberry, Yolanda M.

In: Expert Opinion on Therapeutic Patents, Vol. 23, No. 7, 07.2013, p. 801-815.

Research output: Contribution to journalArticle

@article{78468106ec794ff2b74a5fa7f28ce224,
title = "Plasminogen activator inhibitor-1 inhibitors: A patent review (2006-present)",
abstract = "Introduction: Plasminogen activator inhibitor-1 (PAI-1), the serine protease inhibitor (serpin), binds to and inhibits the plasminogen activators-tissue-type plasminogen activator (tPA) and the urokinase-type plasminogen activator (uPA). This results in both a decrease in plasmin production and a decrease in the dissolution of fibrin clots. Elevated levels of PAI-1 are correlated with an increased risk for cardiovascular disease and have been linked to obesity and metabolic syndrome. Consequently, the pharmacological suppression of PAI-1 might prevent or treat vascular disease. Areas covered: This article provides an overview of the patenting activity on PAI-1 inhibitors. Patents filed by pharmaceutical companies or individual research groups are described, and the biological and biochemical evaluation of the inhibitors, including in vitro and in vivo studies, is discussed. An overview of patents pertaining to using these inhibitors for treating various diseases is also included. Expert opinion: Although there is still no PAI-1 inhibitor being evaluated in a clinical setting or approved for human therapy, research in this field has progressed, and promising new compounds have been designed. Most research has focused on improving the pharmacological profile of these compounds, which will hopefully allow them to proceed to clinical studies. Despite the need for further testing and research, the potential use of PAI-1 inhibitors for treating cardiovascular disease appears quite promising.",
keywords = "Antagonist, Inhibitors, PAI-1, Plasminogen, Serpin",
author = "Fortenberry, {Yolanda M}",
year = "2013",
month = "7",
doi = "10.1517/13543776.2013.782393",
language = "English (US)",
volume = "23",
pages = "801--815",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Plasminogen activator inhibitor-1 inhibitors

T2 - A patent review (2006-present)

AU - Fortenberry, Yolanda M

PY - 2013/7

Y1 - 2013/7

N2 - Introduction: Plasminogen activator inhibitor-1 (PAI-1), the serine protease inhibitor (serpin), binds to and inhibits the plasminogen activators-tissue-type plasminogen activator (tPA) and the urokinase-type plasminogen activator (uPA). This results in both a decrease in plasmin production and a decrease in the dissolution of fibrin clots. Elevated levels of PAI-1 are correlated with an increased risk for cardiovascular disease and have been linked to obesity and metabolic syndrome. Consequently, the pharmacological suppression of PAI-1 might prevent or treat vascular disease. Areas covered: This article provides an overview of the patenting activity on PAI-1 inhibitors. Patents filed by pharmaceutical companies or individual research groups are described, and the biological and biochemical evaluation of the inhibitors, including in vitro and in vivo studies, is discussed. An overview of patents pertaining to using these inhibitors for treating various diseases is also included. Expert opinion: Although there is still no PAI-1 inhibitor being evaluated in a clinical setting or approved for human therapy, research in this field has progressed, and promising new compounds have been designed. Most research has focused on improving the pharmacological profile of these compounds, which will hopefully allow them to proceed to clinical studies. Despite the need for further testing and research, the potential use of PAI-1 inhibitors for treating cardiovascular disease appears quite promising.

AB - Introduction: Plasminogen activator inhibitor-1 (PAI-1), the serine protease inhibitor (serpin), binds to and inhibits the plasminogen activators-tissue-type plasminogen activator (tPA) and the urokinase-type plasminogen activator (uPA). This results in both a decrease in plasmin production and a decrease in the dissolution of fibrin clots. Elevated levels of PAI-1 are correlated with an increased risk for cardiovascular disease and have been linked to obesity and metabolic syndrome. Consequently, the pharmacological suppression of PAI-1 might prevent or treat vascular disease. Areas covered: This article provides an overview of the patenting activity on PAI-1 inhibitors. Patents filed by pharmaceutical companies or individual research groups are described, and the biological and biochemical evaluation of the inhibitors, including in vitro and in vivo studies, is discussed. An overview of patents pertaining to using these inhibitors for treating various diseases is also included. Expert opinion: Although there is still no PAI-1 inhibitor being evaluated in a clinical setting or approved for human therapy, research in this field has progressed, and promising new compounds have been designed. Most research has focused on improving the pharmacological profile of these compounds, which will hopefully allow them to proceed to clinical studies. Despite the need for further testing and research, the potential use of PAI-1 inhibitors for treating cardiovascular disease appears quite promising.

KW - Antagonist

KW - Inhibitors

KW - PAI-1

KW - Plasminogen

KW - Serpin

UR - http://www.scopus.com/inward/record.url?scp=84879333770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879333770&partnerID=8YFLogxK

U2 - 10.1517/13543776.2013.782393

DO - 10.1517/13543776.2013.782393

M3 - Article

VL - 23

SP - 801

EP - 815

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 7

ER -